The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
Clinical trial NCT06396585 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06396585
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2025-08-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.